|Bid||3.8200 x 2900|
|Ask||3.8300 x 4000|
|Day's Range||3.8200 - 4.2700|
|52 Week Range||1.2300 - 5.5000|
|Beta (5Y Monthly)||1.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.50|
Shareholders in Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) may be thrilled to learn that the analysts have just...
Rigel (RIGL) delivered earnings and revenue surprises of -10.00% and 0.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2020, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.